NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $19.00 target price on the stock.

A number of other equities research analysts also recently issued reports on NRXP. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.27 on Monday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $7.33. The company has a 50-day simple moving average of $1.39 and a two-hundred day simple moving average of $2.15. The company has a market capitalization of $15.35 million, a price-to-earnings ratio of -0.59 and a beta of 1.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals as of its most recent SEC filing. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.